Orexin A-mediated AKT signaling in the dentate gyrus contributes to the acquisition, expression and reinstatement of morphine-induced conditioned place preference. 2016

Sui-Jun Guo, and Yu Cui, and Zhen-Zhen Huang, and Huan Liu, and Xue-Qin Zhang, and Jin-Xiang Jiang, and Wen-Jun Xin
Department of Psychology, Guangzhou Medical University, China.

Accumulating evidence indicates that the hippocampal dentate gyrus (DG), a critical brain region contributing to learning and memory, is involved in the addiction and relapse to abused drugs. Emerging studies also suggest the role of orexin signaling in the rewarding behavior induced by repeated exposure to opiates. In the present study, we investigated the dynamic adaptation of orexin signaling in the DG and its functional significance in the acquisition, expression, maintenance of and relapse to rewarding behavior induced by morphine. Repeated place conditioning with morphine significantly increased the orexin A content released from the lateral hypothalamic area projecting neurons into the DG. Local infusions of orexin A into the DG sensitized the acquisition of and relapse to the conditioned place preference induced by morphine. The application of the orexin receptor type 1 (OXR1) antagonist SB334867 significantly abolished the acquisition, expression and maintenance of the conditioned place preference induced by repeated exposure to morphine. Furthermore, the significant increase of the phosphorylation of AKT in the DG was associated with preference for the morphine-paired chamber in rats, which was reversed by the local administration of an OXR1 antagonist. Thus, these findings suggested that the dynamic upregulation of orexin A signaling, via the AKT pathway in the DG, may promote the acquisition and maintenance of opioid-induced craving behaviors and may increase sensitivity to the rewarding effect of subsequent opioids.

UI MeSH Term Description Entries
D007026 Hypothalamic Area, Lateral Area in the hypothalamus bounded medially by the mammillothalamic tract and the anterior column of the FORNIX (BRAIN). The medial edge of the INTERNAL CAPSULE and the subthalamic region form its lateral boundary. It contains the lateral hypothalamic nucleus, tuberomammillary nucleus, lateral tuberal nuclei, and fibers of the MEDIAL FOREBRAIN BUNDLE. Lateral Hypothalamic Area,Lateral Hypothalamic Nucleus,Tuberomammillary Nucleus,Accessory Nucleus of the Ventral Horn,Area Hypothalamica Lateralis,Area Lateralis Hypothalami,Lateral Hypothalamus,Lateral Tuberal Nuclei,Lateral Tuberal Nucleus,Area Hypothalamica Laterali,Area Lateralis Hypothalamus,Area, Lateral Hypothalamic,Areas, Lateral Hypothalamic,Hypothalami, Area Lateralis,Hypothalamic Areas, Lateral,Hypothalamic Nucleus, Lateral,Hypothalamica Laterali, Area,Hypothalamica Lateralis, Area,Hypothalamus, Area Lateralis,Hypothalamus, Lateral,Lateral Hypothalamic Areas,Laterali, Area Hypothalamica,Lateralis Hypothalami, Area,Lateralis Hypothalamus, Area,Lateralis, Area Hypothalamica,Nuclei, Lateral Tuberal,Nucleus, Lateral Hypothalamic,Nucleus, Lateral Tuberal,Nucleus, Tuberomammillary,Tuberal Nuclei, Lateral,Tuberal Nucleus, Lateral
D008297 Male Males
D009020 Morphine The principal alkaloid in opium and the prototype opiate analgesic and narcotic. Morphine has widespread effects in the central nervous system and on smooth muscle. Morphine Sulfate,Duramorph,MS Contin,Morphia,Morphine Chloride,Morphine Sulfate (2:1), Anhydrous,Morphine Sulfate (2:1), Pentahydrate,Oramorph SR,SDZ 202-250,SDZ202-250,Chloride, Morphine,Contin, MS,SDZ 202 250,SDZ 202250,SDZ202 250,SDZ202250,Sulfate, Morphine
D009287 Naphthyridines A group of two-ring heterocyclic compounds consisting of a NAPHTHALENES double ring in which two carbon atoms, one per each ring, are replaced with nitrogens.
D009293 Opioid-Related Disorders Disorders related to or resulting from abuse or misuse of OPIOIDS. Opiate Addiction,Opiate Dependence,Opioid Misuse,Opioid Use Disorder,Prescription Opioid Abuse,Prescription Opioid Misuse,Addiction, Opioid,Dependence, Opioid,Opiate Abuse,Opioid Abuse,Opioid Addiction,Opioid Dependence,Abuse, Opiate,Abuse, Opioid,Abuse, Prescription Opioid,Addiction, Opiate,Dependence, Opiate,Disorder, Opioid Use,Misuse, Opioid,Misuse, Prescription Opioid,Opiate Abuses,Opioid Abuse, Prescription,Opioid Abuses,Opioid Addictions,Opioid Dependences,Opioid Misuses,Opioid Related Disorders,Opioid Use Disorders,Opioid-Related Disorder,Prescription Opioid Abuses,Prescription Opioid Misuses
D002755 Choice Behavior The act of making a selection among two or more alternatives, usually after a period of deliberation. Approach Behavior,Approach Behaviors,Behavior, Approach,Behavior, Choice,Behaviors, Approach,Behaviors, Choice,Choice Behaviors
D003213 Conditioning, Psychological Simple form of learning involving the formation, strengthening, or weakening of an association between a stimulus and a response. Conditioning, Psychology,Psychological Conditioning,Social Learning Theory,Social Learning Theories,Theory, Social Learning
D004195 Disease Models, Animal Naturally-occurring or experimentally-induced animal diseases with pathological processes analogous to human diseases. Animal Disease Model,Animal Disease Models,Disease Model, Animal
D000068796 Orexin Receptor Antagonists Substances that bind to and inhibit the action of OREXIN RECEPTORS. Drugs in this class have been used as SLEEP AIDS, PHARMACEUTICAL. Dual Orexin Receptor Antagonist,Orexin Receptor Antagonist,Dual Orexin Receptor Antagonists,Orexin Receptor Blockers,Antagonist, Orexin Receptor,Receptor Antagonist, Orexin
D000068797 Orexins Neuropeptide hormones that play a role in regulating a variety of behavioral and physiological processes in response to motivational stimuli. Hypocretin,Orexin,Hypocretin-1,Hypocretin-2,Hypocretins,Orexin-A,Orexin-B,Hypocretin 1,Hypocretin 2,Orexin A,Orexin B

Related Publications

Sui-Jun Guo, and Yu Cui, and Zhen-Zhen Huang, and Huan Liu, and Xue-Qin Zhang, and Jin-Xiang Jiang, and Wen-Jun Xin
February 2016, Behavioral neuroscience,
Sui-Jun Guo, and Yu Cui, and Zhen-Zhen Huang, and Huan Liu, and Xue-Qin Zhang, and Jin-Xiang Jiang, and Wen-Jun Xin
April 2016, Neuroscience bulletin,
Sui-Jun Guo, and Yu Cui, and Zhen-Zhen Huang, and Huan Liu, and Xue-Qin Zhang, and Jin-Xiang Jiang, and Wen-Jun Xin
August 2018, Experimental neurology,
Sui-Jun Guo, and Yu Cui, and Zhen-Zhen Huang, and Huan Liu, and Xue-Qin Zhang, and Jin-Xiang Jiang, and Wen-Jun Xin
January 2016, Avicenna journal of phytomedicine,
Sui-Jun Guo, and Yu Cui, and Zhen-Zhen Huang, and Huan Liu, and Xue-Qin Zhang, and Jin-Xiang Jiang, and Wen-Jun Xin
February 2020, Behavioural brain research,
Sui-Jun Guo, and Yu Cui, and Zhen-Zhen Huang, and Huan Liu, and Xue-Qin Zhang, and Jin-Xiang Jiang, and Wen-Jun Xin
January 2017, Avicenna journal of phytomedicine,
Sui-Jun Guo, and Yu Cui, and Zhen-Zhen Huang, and Huan Liu, and Xue-Qin Zhang, and Jin-Xiang Jiang, and Wen-Jun Xin
September 2017, Behavioural brain research,
Sui-Jun Guo, and Yu Cui, and Zhen-Zhen Huang, and Huan Liu, and Xue-Qin Zhang, and Jin-Xiang Jiang, and Wen-Jun Xin
November 2002, Behavioural brain research,
Sui-Jun Guo, and Yu Cui, and Zhen-Zhen Huang, and Huan Liu, and Xue-Qin Zhang, and Jin-Xiang Jiang, and Wen-Jun Xin
January 2015, PloS one,
Sui-Jun Guo, and Yu Cui, and Zhen-Zhen Huang, and Huan Liu, and Xue-Qin Zhang, and Jin-Xiang Jiang, and Wen-Jun Xin
May 2016, Brain research,
Copied contents to your clipboard!